Editas Medicine, Inc.
EDITEditas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How EDIT's past catalysts played out
No drugs found in this phase.
Frequently asked questions
When is Editas Medicine, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Editas Medicine, Inc. (EDIT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EDIT biotech catalysts?→
Add EDIT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Editas Medicine, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.